Maternal Lamotrigine Treatment and Elevated Neonatal Gamma-Glutamyl Transpeptidase

Gal Dubnov-Raz, Rivka Shapiro, Paul Merlob

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Lamotrigine is an antiepileptic drug with a low adverse-effect profile. This report describes an infant born to an epileptic mother treated with lamotrigine, who had a highly elevated gamma-glutamyl transpeptidase level after birth. There was no other clinical or biochemical evidence of liver or bile duct dysfunction. Infant serum level of lamotrigine, which crosses the placenta, was within therapeutic limits. Gamma-glutamyl transpeptidase levels declined slowly during the following months. We suggest that, in the absence of additional markers of tissue damage, the infant's gamma-glutamyl transpeptidase elevation was caused by maternal intake of lamotrigine. Liver function tests should be monitored in infants of lamotrigine treated mothers, as enzyme elevation might still suggest liver damage.

Original languageEnglish
Pages (from-to)220-222
Number of pages3
JournalPediatric Neurology
Volume35
Issue number3
DOIs
StatePublished - Sep 2006
Externally publishedYes

Fingerprint

Dive into the research topics of 'Maternal Lamotrigine Treatment and Elevated Neonatal Gamma-Glutamyl Transpeptidase'. Together they form a unique fingerprint.

Cite this